MAPT and Parkinson disease: This combination best distinguishes PD from CBS, although the relative rarity of CBS makes widespread testing in PD trials of modest value.119,120 Preliminary evidence suggests that ultrasensitive tau SAA may identify/exclude patients with tauopathies from PD at trial recruitment,121 although a combined assay with α-syn would be more ideal.